Aktiv-Neb: A Dry Powder Inhaler for Anti-RSV siRNA Microparticles

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$99,990.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43HD057671-01
Agency Tracking Number:
HD057671
Solicitation Year:
2008
Solicitation Topic Code:
N/A
Solicitation Number:
PHS2007-2
Small Business Information
AKTIV-DRY, LLC
AKTIV-DRY, LLC, 6060 SPINE RD, BOULDER, CO, 80302
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
136952087
Principal Investigator
 () -
Business Contact
Phone: (303) 350-3060
Email: bquinn@aktiv-dry.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I project aims to develop a novel dry powder inhalation system, Aktiv-NebTM, for delivering antiviral drug (siRNAs) powders, to the respiratory systems of infants and young children as an intervention strategy for respiratory infection RSV. RSV-specific siRNAs developed by Alnylam Pharmaceuticals, have been demonstrated to be efficacious and specific using in vitro and in vivo models of RSV infection and safe and well tolerat ed in ongoing human trials focused on intranasal and aerosol delivery. Aktiv-Dry's novel, patented powder generating technology, CO2-assisted nebulization with a bubble dryer (CAN-BD(r)), will be applied to make inhalable powders of placebo and siRNA drugs (ranging between 1- 5 microns). The proposed inhalation system will be capable of delivering a continuous stream of micronized dry powder aerosol into the respiratory tract of children. The performance of Aktiv-NebTM inhaler will be judged based on three criteria; the emitted aerosol size distribution, the consistency of emitted dose over the duration of run, and the reproducibility at physiologically relevant breathing patterns for children and infants. The system will be calibrated with placebo powders a nd the effect of flow rates, dosage, and delivery time on the aerosol generation will be studied. The optimized inhalation system will be applied to CAN-BD processed siRNA microparticle powders and formulations with and without excipients will be studied a nd evaluated. The expected outcome of the Phase I effort is a critical evaluation on the feasibility of a novel dry powder inhalation system, for enabling the delivery of siRNA powders, to the respiratory system. A safe, effective, stable, and economical f ormulation strategy for siRNA delivery to the lungs would have tremendous commercial applications for issues related to public health and biodefense. PUBLIC HEALTH RELEVANCE: The project aims to develop and demonstrate the feasibility of a novel dry powder inhalation system, Aktiv-NebTM, for delivering antiviral drug (siRNA) powders to the respiratory systems of young children as an intervention strategy for viral infection.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government